The selection team of the BaseLaunch accelerator has selected four companies that are specializing in oncology and neurodegenerative diseases to proceed to the second phase of the program. One company is in stealth mode.
The BaseLaunch program is a two-phase accelerator program in which selected startups receive support from an experienced team from the healthcare industry over a period of 15 months. In the first phase, 15 startups joined the program and now only four will proceed to the next round. These include:
PharmaBiome – is a spinoff from the ETH Zurich developing a new generation of microbiome therapies based on itsmixed-culture technology, for the treatment of intestinal diseases.
TOLREMO – is developing a resistance-preventing small molecules to boost the long-term efficacy of existing cancer drugs to prolong patient survival. Its therapeutic approach specifically eradicates cancer cells that ultimately cause drug resistance. The company plans to use its molecules alongside diagnostic solutions to ensure that the right patient is treated with the right drug at the right time.
Synoesis (New York)– is developing a first-in-class therapeutic to stop Parkinson’s disease.
The company in stealth mode remains undisclosed.
Over the next 12 months, each project will receive grants of up to 250,000 Swiss francs to help the startups reach the next key milestones. Additionally, the teams will benefit from free support from advisors and experienced healthcare entrepreneurs who will be covering a range of topics from business development, legal aspect to science and preclinical development. BaseLaunch is also offering the teams free access to equipped ready-to-use labs at the Switzerland Innovation Park Basel Area in Allschwil.
(Press release - RAN)
0Comments
Please login or sign up to comment.
Commenting guidelines